VERA - Vera Therapeutics: Waiting For A Pullback

2024-04-03 13:38:39 ET

Summary

• The stock of Vera Therapeutics, Inc. has surged following positive trial data for its lead product candidate, atacicept.
• Atacicept could become a best-of-breed drug in the large IgAN space, but its potential launch is not until 2026 if all goes to schedule.
• The company recently executed a successful secondary offering, providing it needed funding to push the development of atacicept forward.
• Still more upside ahead for Vera Therapeutics?  An analysis follows in the paragraphs below.

Today, we put Vera Therapeutics, Inc. ( VERA ) in the spotlight. The stock has had a huge move up following positive trial data for its lead product candidate. The company has used the increase in market value to execute a large secondary offering to raise additional capital. There was some also some significant insider selling in the back half of March. A sign the shares have come too far, too fast? An analysis follows in the paragraphs below....

For further details see: